Lufthansa CEO lined up to replace Roche's Humer
This article was originally published in Scrip
Roche has named Christoph Franz, chairman and CEO of Lufthansa since 2011, as the man who will fill chairman Franz Humer's shoes when he stands down in 2014. Dr Franz is to depart from Lufthansa when his three-year contract is complete in May 2014.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.